Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NEUP Neuphoria Therapeutics Inc

休市中 05-29 16:00:00 EDT

5.31

-0.05

-0.93%

盘后5.31

+0.000.00%

19:46 EDT

最高5.39	最低5.20	成交量2.03万
今开5.39	昨收5.36	日振幅3.54%
总市值2,870万	流通市值2,054万	总股本540.46万
成交额10.70万	换手率0.52%	流通股本386.78万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NEUP","market":"US","secType":"STK","nameCN":"Neuphoria Therapeutics Inc","latestPrice":5.31,"timestamp":1780084800000,"preClose":5.36,"halted":0,"volume":20301,"hourTrading":{"tag":"盘后","latestPrice":5.31,"preClose":5.31,"latestTime":"19:46 EDT","volume":3,"amount":15.8474,"timestamp":1780098376370,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.009328358208955357,"floatShares":3867799,"shares":5404551,"eps":-4.95453,"marketStatus":"休市中","change":-0.05,"latestTime":"05-29 16:00:00 EDT","open":5.39,"high":5.39,"low":5.2,"amount":106973.26923959999,"amplitude":0.035448,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.95453,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":5.36,"postHourTrading":{"tag":"盘后","latestPrice":5.31,"preClose":5.31,"latestTime":"19:46 EDT","volume":3,"amount":15.8474,"timestamp":1780098376370,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.34500984053004813},"requestUrl":"/m/hq/s/NEUP","defaultTab":"news","newsList":[{"id":"1112665789","title":"Lynx1资本管理公司于12月26日提出以现金或等值股票收购Neuphoria Therapeutics的知识产权资产——美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1112665789","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112665789?lang=zh_cn&edition=full","pubTime":"2025-12-30 05:41","pubTimestamp":1767044474,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件，Lynx1资本管理公司已于12月26日正式向Neuphoria Therapeutics Inc（NEUP）提出收购要约，计划以现金或等值股票方式获取该公司的知识产权资产。\n这一举措标志着资本市场对生物科技领域知识产权价值的持续关注。通过现金与股权结合的灵活收购方案，Lynx1资本管理展现出其对Neuphoria Therapeutics核心资产战略价值的认可，同时也为交易双方提供了多元化的合作路径。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186846363","title":"知名代理顾问公司ISS建议股东使用白色代理卡为Neuphoria的两位董事提名人投票","url":"https://stock-news.laohu8.com/highlight/detail?id=1186846363","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186846363?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:07","pubTimestamp":1765199235,"startTime":"0","endTime":"0","summary":"知名代理顾问公司ISS建议股东使用白色代理卡为Neuphoria的两位董事提名人投票","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178607496","title":"Neuphoria Therapeutics Inc - 敦促股东在白色代理卡上投票支持Neuphoria的两名提名人","url":"https://stock-news.laohu8.com/highlight/detail?id=1178607496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178607496?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:05","pubTimestamp":1764853516,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc - 敦促股东在白色代理卡上投票支持Neuphoria的两名提名人","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164604292","title":"Neuphoria Therapeutics Inc - 暂停Bnc210在创伤后应激障碍方面的研发支出，并在公司战略评估中评估所有可能性","url":"https://stock-news.laohu8.com/highlight/detail?id=1164604292","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164604292?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:03","pubTimestamp":1764853402,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc - 暂停Bnc210在创伤后应激障碍方面的研发支出，并在公司战略评估中评估所有可能性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127135911","title":"Lynx1 Capital Management向Neuphoria Therapeutics提出非约束性收购提议，报价为每股4.75美元现金","url":"https://stock-news.laohu8.com/highlight/detail?id=1127135911","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127135911?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:35","pubTimestamp":1764682510,"startTime":"0","endTime":"0","summary":"Lynx1 Capital Management向Neuphoria Therapeutics提出非约束性提议，计划以每股4.75美元的现金收购其所有流通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188165374","title":"Lynx1 Capital Management Lp 于12月2日向Neuphoria Therapeutics董事会提交函件 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1188165374","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188165374?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:32","pubTimestamp":1764682337,"startTime":"0","endTime":"0","summary":"Lynx1 Capital Management Lp 于12月2日向Neuphoria Therapeutics董事会提交函件 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neuphoriatx.com","stockEarnings":[{"period":"1week","weight":-0.031},{"period":"1month","weight":0.0231},{"period":"3month","weight":0.2795},{"period":"6month","weight":0.1748},{"period":"1year","weight":-0.1806},{"period":"ytd","weight":0.3686}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neuphoria Therapeutics Inc.（原名Bionomics Limited）于1996年根据澳大利亚法律注册成立，并于2024年12月24日迁移至特拉华州并成为美国公司。作为一家临床阶段的生物技术公司，它开发神经精神障碍疗法。其主要候选药物BNC210（口服选择性α 7烟碱性ACH受体调节剂）针对急性SAD和慢性PTSD，超过2700万美国患者的需求未得到满足。BNC210是一种首创的抗焦虑疗法，可在没有镇静、认知问题或成瘾的情况下快速恢复神经递质平衡。它与默沙东（美国/加拿大以外）就两种早期临床CNS药物建立了合作伙伴关系。其管线包括下一代α 7受体和KV3.1/3.2临床前项目（先导优化）。目前的治疗方法（抗抑郁药、苯二氮卓类药物）几十年来缺乏FDA的新批准，存在缺陷；BNC210在试验中显示出快速的作用和没有限制性副作用。","exchange":"NASDAQ","name":"Neuphoria Therapeutics Inc","nameEN":"Neuphoria Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Neuphoria Therapeutics Inc(NEUP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Neuphoria Therapeutics Inc,NEUP,Neuphoria Therapeutics Inc股票,Neuphoria Therapeutics Inc股票老虎,Neuphoria Therapeutics Inc股票老虎国际,Neuphoria Therapeutics Inc行情,Neuphoria Therapeutics Inc股票行情,Neuphoria Therapeutics Inc股价,Neuphoria Therapeutics Inc股市,Neuphoria Therapeutics Inc股票价格,Neuphoria Therapeutics Inc股票交易,Neuphoria Therapeutics Inc股票购买,Neuphoria Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Neuphoria Therapeutics Inc(NEUP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}